HMGB1 and neoplasm: Given that considerable progress has been made in HMGB1-targeted therapy in multiple inflammatory conditions, especially in blocking the production of excessive amounts of the extracellular disulfide HMGB1 isoform, which provides constitutes an attractive clinical opportunity to ameliorate systemic inflammatory diseases [64], and extracellular HMGB1 blockade also controls tumor progression by remodeling the immune microenvironment [28].